[Angiogenic factors can be used when pre-eclampsia is suspected]

Area of Science:

• Obstetrics and Gynecology
• Maternal-Fetal Medicine
• Reproductive Biology

Background:

• Pre-eclampsia affects 7% of pregnancies, presenting significant diagnostic and predictive challenges due to its heterogeneous nature.
• Current predictive models for pre-eclampsia and its complications exhibit low accuracy.
• Angiogenic factors, specifically placental growth factor (PlGF) and soluble fms-like tyrosin kinase 1 (sFlt-1), show altered levels in pre-eclamptic pregnancies.

Purpose of the Study:

• To evaluate the potential of angiogenic factors, placental growth factor (PlGF) and soluble fms-like tyrosin kinase 1 (sFlt-1), and their ratio in assessing pre-eclampsia development and complications.
• To highlight the need for establishing and validating cut-off values for these angiogenic factors in clinical practice.

Main Methods:

• Comparative analysis of angiogenic factor levels (PlGF, sFlt-1) and the sFlt-1/PlGF ratio between women with and without pre-eclampsia.
• Review of existing studies indicating differences in these biomarkers.

Main Results:

• Significant differences observed in PlGF and sFlt-1 levels, as well as the sFlt-1/PlGF ratio, between pre-eclamptic and non-pre-eclamptic pregnancies.
• Evidence suggests these angiogenic factors can aid in identifying women at risk of pre-eclampsia complications.

Conclusions:

• The sFlt-1/PlGF ratio and individual angiogenic factors show promise for improving pre-eclampsia diagnosis and risk stratification.
• Further research is required to establish and validate specific cut-off levels for clinical implementation.